Skip to main content

Table 3 Multivariate analysis in overall patients according to AJCC or BCLC tumor stage

From: Protein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation

Characteristics Hazard ratio (95% CI) P value*
AJCC Tumor stage 2.775 (1.815-4.243) < 0.001
Portal vein thrombosis 1.573 (0.912-2.715) 0.103
Serum AFP (≥ 400 ng/mL) 1.153 (0.688-1.919) 0.584
Serum PIVKA-II (≥ 300 mAU/mL) 2.718 (1.535-4.812) 0.001
Platelet count (≤ 130 × 103/μL) 1.830 (1.130-2.964) 0.014
BCLC Tumor stage 1.210 (1.047-1.400) 0.010
Portal vein thrombosis 1.934 (1.094-3.422) 0.023
Serum AFP (≥ 400 ng/mL) 1.470 (0.888-2.433) 0.133
Serum PIVKA-II (≥ 300 mAU/mL) 3.688 (2.073-6.560) < 0.001
Platelet count (≤ 130 × 103/μL) 1.911 (1.187-3.076) 0.008
  1. Abbreviation: AFP, alpha-fetoprotein; PIVKA-II, Protein induced by vitamin K absence or antagonist-II;
  2. *P-values for each clinical variable calculated using Cox regression analysis.